Breo Ellipta now approved for use in children

FDA has expanded the indication for fluticasone furoate/vilanterol inhaled (Breo Ellipta) to include maintenance treatment of asthma in children ages 5 years and older. Previously it had been approved for asthma treatment only in adults.